A detailed history of Wetherby Asset Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wetherby Asset Management Inc holds 5,879 shares of VRTX stock, worth $2.4 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
5,879
Previous 5,963 1.41%
Holding current value
$2.4 Million
Previous $2.79 Million 2.15%
% of portfolio
0.13%
Previous 0.13%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $38,640 - $42,485
-84 Reduced 1.41%
5,879 $2.73 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $11,784 - $14,565
30 Added 0.51%
5,963 $2.79 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $5,299 - $5,799
-13 Reduced 0.22%
5,933 $2.48 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $4,802 - $5,749
14 Added 0.24%
5,946 $2.42 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $36,185 - $38,783
107 Added 1.84%
5,932 $2.06 Million
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $56,281 - $62,991
-179 Reduced 2.98%
5,825 $2.05 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $60,327 - $68,820
213 Added 3.68%
6,004 $1.89 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $12,287 - $13,823
43 Added 0.75%
5,791 $1.67 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $147,868 - $164,986
540 Added 10.37%
5,748 $1.66 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $104,557 - $130,184
-445 Reduced 7.87%
5,208 $1.47 Million
Q1 2022

May 16, 2022

BUY
$221.42 - $260.97 $94,103 - $110,912
425 Added 8.13%
5,653 $1.48 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $203,207 - $256,520
1,148 Added 28.14%
5,228 $1.15 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $59,314 - $66,377
-327 Reduced 7.42%
4,080 $740,000
Q2 2021

Aug 16, 2021

SELL
$187.49 - $221.1 $73,121 - $86,229
-390 Reduced 8.13%
4,407 $889,000
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $60,035 - $69,979
-290 Reduced 5.7%
4,797 $1.03 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $965,080 - $1.29 Million
4,662 Added 1096.94%
5,087 $1.2 Million
Q3 2020

Dec 16, 2020

SELL
$255.65 - $303.1 $1.22 Million - $1.44 Million
-4,754 Reduced 91.79%
425 $116,000
Q3 2020

Dec 16, 2020

SELL
$255.65 - $303.1 $113,508 - $134,576
-444 Reduced 7.9%
5,179 $1.41 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $24,798 - $29,400
-97 Reduced 1.7%
5,623 $1.53 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $14,656 - $19,227
65 Added 1.15%
5,720 $1.66 Million
Q1 2020

May 06, 2020

BUY
$199.77 - $247.81 $89,696 - $111,266
449 Added 8.62%
5,655 $1.35 Million
Q4 2019

Jan 28, 2020

BUY
$166.71 - $223.91 $29,507 - $39,632
177 Added 3.52%
5,206 $1.14 Million
Q3 2019

Oct 31, 2019

BUY
$166.23 - $187.09 $43,219 - $48,643
260 Added 5.45%
5,029 $852,000
Q2 2019

Jul 25, 2019

BUY
$164.61 - $190.37 $13,662 - $15,800
83 Added 1.77%
4,769 $874,000
Q1 2019

May 09, 2019

BUY
$163.73 - $194.7 $22,431 - $26,673
137 Added 3.01%
4,686 $862,000
Q4 2018

Jan 30, 2019

BUY
$151.91 - $192.21 $45,117 - $57,086
297 Added 6.98%
4,549 $754,000
Q3 2018

Nov 07, 2018

BUY
$167.73 - $192.74 $37,739 - $43,366
225 Added 5.59%
4,252 $820,000
Q2 2018

Jul 24, 2018

SELL
$145.72 - $169.96 $7,431 - $8,667
-51 Reduced 1.25%
4,027 $684,000
Q1 2018

May 04, 2018

BUY
$151.6 - $177.13 $56,850 - $66,423
375 Added 10.13%
4,078 $665,000
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $8,511 - $9,644
62 Added 1.7%
3,703 $555,000
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $539,341 - $590,715
3,641
3,641 $554,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wetherby Asset Management Inc Portfolio

Follow Wetherby Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wetherby Asset Management Inc with notifications on news.